Adoptive Cellular Therapy for Solid Tumors.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cancer immunotherapy encompasses diverse tools like antibodies, vaccines, and cellular therapies.
• Adoptive cellular therapy (ACT) involves ex vivo expansion and reinfusion of patient immune cells, primarily T cells.
• Key T-cell strategies include tumor-infiltrating lymphocytes, T-cell receptor T cells, and CAR T cells, functioning as 'living drugs'.

Purpose of the Study:

• This review focuses on ACT, detailing its mechanisms, challenges, and advancements.
• It explores strategies to overcome limitations in solid tumor treatment.
• The review also covers gene editing technologies and toxicity management in ACT.

Main Methods:

• The review synthesizes current knowledge on ACT, including T-cell isolation, expansion, and reinfusion.
• It discusses transgene expression and gene editing (e.g., CRISPR/Cas9) to enhance anti-tumor activity.
• Methods for mitigating common toxicities associated with ACT are also examined.

Main Results:

• ACT strategies like CAR T cells have achieved durable remissions in some patients.
• Challenges in solid tumors include poor cell homing, proliferation, and survival.
• Gene editing offers potential for enhanced anti-tumor activity and overcoming tumor-induced resistance.

Conclusions:

• Adoptive cellular therapy holds significant potential as a cancer treatment, particularly with advancements in genetic engineering.
• Overcoming hurdles in solid tumor treatment and managing toxicities are critical for broader clinical success.
• Gene editing technologies are poised to further refine and improve the efficacy of cellular immunotherapies.